當前位置：首頁 SCI期刊 SCIE期刊醫學中科院4區 JCRQ2 期刊介紹(非官網)

Cancer Biology & TherapySCIE

國際簡稱：CANCER BIOL THER 參考譯名：癌癥生物學與治療

中科院分區
4區
CiteScore分區
Q1
JCR分區
Q2

基本信息：: ISSN：1538-4047; E-ISSN：1555-8576; 是否OA：未開放; 是否預警：否; TOP期刊：否

出版信息：: 出版地區：UNITED STATES; 出版商：Landes Bioscience; 出版語言：English; 出版周期：Monthly; 出版年份：2002; 研究方向：醫學-腫瘤學

評價信息：: 影響因子：4.4; H-index：101; CiteScore指數：7; SJR指數：0.914; SNIP指數：0.688

發文數據：: Gold OA文章占比：79.27%; 研究類文章占比：93.83%; 年發文量：81; 自引率：0; 開源占比：0.4241; 出版撤稿占比：0.0090...; 出版國人文章占比：0.55; OA被引用占比：0.1635...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區 JCR分區發文數據常見問題

英文簡介Cancer Biology & Therapy期刊介紹

Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.

期刊簡介Cancer Biology & Therapy期刊介紹

《Cancer Biology & Therapy》自2002出版以來，是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間：約2.3月
醫學
ONCOLOGY
SCIE
中科院4區
非預警

Cite Score數據（2024年最新版）Cancer Biology & Therapy Cite Score數據

CiteScore：7
SJR：0.914
SNIP：0.688

學科類別	分區	排名	百分位
大類：Medicine 小類：Oncology	Q1	94 / 404	76%
大類：Medicine 小類：Pharmacology	Q2	90 / 313	71%
大類：Medicine 小類：Cancer Research	Q2	82 / 230	64%
大類：Medicine 小類：Molecular Medicine	Q2	65 / 178	63%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Cancer Biology & Therapy 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區	小類學科	分區
醫學	4區	ONCOLOGY 腫瘤學	4區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區Cancer Biology & Therapy JCR分區

2023-2024 年最新版

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：ONCOLOGY	SCIE	Q2	86 / 322	73.4%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：ONCOLOGY	SCIE	Q2	98 / 322	69.72%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區，這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計

國家/地區數量
CHINA MAINLAND291
USA133
Italy13
India10
Japan9
England8
GERMANY (FED REP GER)6
South Korea6
Brazil4
Poland4

本刊中國學者近年發表論文

1、The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
Author: Sun Y¹, Wang P², Yang W¹, Shan Y¹, Zhang Q¹, Wu H³.

Journal: Cancer Biol Ther. 2019;20(6):729-739. doi: 10.1080/15384047.2018.1529121. Epub 2019 Mar 27.
2、EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
Author: Lei T¹, Zhu X², Zhu K², Jia F¹, Li S¹.

Journal: Cancer Biol Ther. 2019 Mar 31:1-10. doi: 10.1080/15384047.2019.1595276. [Epub ahead of print]
3、Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Author: Zhu X¹, Zhang Q², Wang D¹, Liu C¹, Han B², Yang JM³.

Journal: Cancer Biol Ther. 2019 Mar 31:1-8. doi: 10.1080/15384047.2019.1595282. [Epub ahead of print]
4、Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.
Author: Wang D¹, Qian G¹, Wang J¹, Wang T¹, Zhang L¹, Yang P¹, Lin F¹.

Journal: Cancer Biol Ther. 2019 Apr 12:1-8. doi: 10.1080/15384047.2019.1591675. [Epub ahead of print]
5、The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis.
Author: Zhou Y¹, Yin L², Li H¹, Liu LH¹, Xiao T¹.

Journal: Cancer Biol Ther. 2019 Apr 12:1-8. doi: 10.1080/15384047.2019.1598766. [Epub ahead of print]
6、A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma.
Author: Zhang B¹, Chen M¹, Jiang N¹, Shi K¹, Qian R¹.

Journal: Cancer Biol Ther. 2019 Apr 12:1-9. doi: 10.1080/15384047.2019.1598762. [Epub ahead of print]
7、Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway.
Author: Zhang C¹, Bao C², Zhang X², Lin X², Pan D¹, Chen Y².

Journal: Cancer Biol Ther. 2019 Apr 14:1-10. doi: 10.1080/15384047.2019.1599671. [Epub ahead of print]
8、Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Author: Jing W^1,², Yan W^1,³, Liu Y⁴, Li J^1,³, Yu J^1,³, Zhu H^1,³.

Journal: Cancer Biol Ther. 2019 Apr 14:1-6. doi: 10.1080/15384047.2019.1598760. [Epub ahead of print]